QuantX Biosciences, Inc.

QuantX Biosciences, Inc. is a US-based biopharmaceutical company focused on developing innovative oral small molecule therapeutics to address immunology and inflammation challenges. Founded in 2022, QuantX Biosciences, Inc. operates out of Princeton, US, and specializes in drug discovery within the biopharmaceutical sector.

The company has successfully raised funding through two deals, with the latest being a Series B round. The most recent funding occurred on February 9, 2026, totaling USD 85. 00 mn, with involvement from investors like Lilly Asia Ventures and Sanofi Ventures. This capital was raised to enhance ongoing clinical programs for their STAT6 and IL-17 oral candidates.

The founder's previous endeavors are not available, nor is information about any subsidiaries. QuantX specializes in the discovery and development of innovative oral small molecule therapeutics, targeting validated areas in immunology and inflammation. Utilizing a proprietary computational platform, the company enhances the discovery process for superior drug candidates, allowing for significant optimization of these compounds. Their main product offerings focus on a pipeline of oral small molecules designed to address clinically validated therapeutic targets, catering to healthcare providers and pharmaceutical partners involved in treating inflammatory and immunological conditions.

QuantX serves a diverse client base, including biotechnology firms, pharmaceutical companies, and clinical research organizations, primarily in North America and Europe. QuantX’s revenue model is primarily based on partnerships and collaborations with pharmaceutical and biotechnology companies, where they offer their drug discovery services in exchange for funding and milestone payments. These transactions are structured around collaborative agreements, which can include research and development funding, shared royalties on products developed, and other performance-based incentives. Specific pricing plans for their services are aligned with the complexity and scope of the projects undertaken, which may involve both upfront payments and success-based fees depending on the achievement of agreed-upon milestones.

By focusing on the development of proprietary drug candidates and optimizing them through their computational platform, QuantX aims to create substantial value in its collaborations while advancing its product pipeline in the highly competitive biopharmaceutical market. In February 2026, QuantX Biosciences, Inc. raised USD 85. 00 mn in Series B funding to support its clinical programs for the STAT6 and IL-17 oral candidates and to develop additional therapies targeting immunology and inflammation.

The company plans to launch new products focused on these therapeutic areas and expand its presence in both North American and European markets. Future strategies will leverage the recent funding to enhance research capabilities and accelerate timelines for product development.